Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

This study is testing a new oral pill called DZD6008 for adults with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. EGFR mutations tell cancer cells to grow, and drugs that block this signal can slow the cancer. Researchers want to find out if DZD6008 is safe and effective, especially for people whose cancer stopped responding to previous EGFR-targeting drugs. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic NSCLC - Your tumor has a specific EGFR mutation (Exon 19 deletion or L858R) - You have already tried at least one EGFR-targeted drug and/or chemotherapy (for some parts of the study), or you have not yet started treatment (for other parts) - Your cancer is measurable on scans and you are reasonably functional day-to-day **You may NOT be eligible if...** - Your cancer has a different or unusual EGFR mutation type - Your lung cancer has mixed small cell features - You have had certain other cancers within the past 2 years - You have active infections such as HIV, hepatitis B or C, or active COVID-19 - You have a history of serious lung inflammation (interstitial lung disease) Talk to your doctor to see if this trial is right for you.